454 related articles for article (PubMed ID: 26677336)
41. Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.
Durm G; Hanna N
Future Oncol; 2014 May; 10(7):1167-73. PubMed ID: 24947258
[TBL] [Abstract][Full Text] [Related]
42. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Van Cutsem E; Prenen H; D'Haens G; Bennouna J; Carrato A; Ducreux M; Bouché O; Sobrero A; Latini L; Staines H; Oum'Hamed Z; Dressler H; Studeny M; Capdevila J
Ann Oncol; 2015 Oct; 26(10):2085-91. PubMed ID: 26272806
[TBL] [Abstract][Full Text] [Related]
43. BIBF 1120 for the treatment of non-small cell lung cancer.
Reck M
Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
[TBL] [Abstract][Full Text] [Related]
44. Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series.
Hochmair MJ; Kolb R; Wurm R; Zach H; Bittner N
Case Rep Oncol; 2022; 15(1):138-148. PubMed ID: 35350799
[TBL] [Abstract][Full Text] [Related]
45. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
46. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Suzuki N; Nakagawa F; Matsuoka K; Takechi T
Oncol Rep; 2016 Dec; 36(6):3123-3130. PubMed ID: 27805254
[TBL] [Abstract][Full Text] [Related]
47. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
48. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
49. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
50. Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models.
Awasthi N; Schwarz MA; Kaurich Q; Zhang C; Hilberg F; Schwarz RE
Front Oncol; 2023; 13():1145999. PubMed ID: 37234980
[TBL] [Abstract][Full Text] [Related]
51. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
52. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
53. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.
Davidson BA; Secord AA
Int J Womens Health; 2014; 6():289-300. PubMed ID: 24648773
[TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine.
Trifanescu OG; Anghel R
Maedica (Bucur); 2015 Sep; 10(4):376-381. PubMed ID: 28465743
[TBL] [Abstract][Full Text] [Related]
55. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
56. Integrated therapy of kidney cancer.
Longo R; D'Andrea MR; Sarmiento R; Salerno F; Gasparini G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi141-8. PubMed ID: 17591809
[TBL] [Abstract][Full Text] [Related]
57. Gastric perforation related to concurrent use of nintedanib and ramucirumab.
Takahashi S; Murata S; Yoshino Y; Kobayashi Y; Nakamura M
Respirol Case Rep; 2019 Jan; 7(1):e00383. PubMed ID: 30455955
[TBL] [Abstract][Full Text] [Related]
58. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
59. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Gottfried M; Bennouna J; Bondarenko I; Douillard JY; Heigener DF; Krzakowski M; Mellemgaard A; Novello S; Orlov S; Summers Y; von Pawel J; Stöhr J; Kaiser R; Reck M
Target Oncol; 2017 Aug; 12(4):475-485. PubMed ID: 28702806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
